Delivery Order SPE2DB24D1201-SPE2DB25FJEFE
- Not listed
- The Defense Logistics Agency awarded a $1,187.75 delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens. This is a firm fixed price, competitively awarded contract with a completion date of August 11, 2025, and represents a child delivery order under AmerisourceBergen's larger prime indefinite delivery contract (IDC) with DLA Troop Support Medical. The work will be performed at the contractor's corporate office in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $1,170.98 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 12.5 mg/0.5 mL pen injections on August 29, 2025, with completion scheduled for September 2, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through the federal procurement process. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order valued at $1,632.54 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Mounjaro 10 mg/0.5 ml pen (tirzepatide injection), a diabetes and weight management medication. This is a firm fixed price delivery order with no set-aside designation, indicating competitive award through open competition. The contract is to be completed by August 26, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order valued at $4,081.35 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 10, 2025. This firm fixed price delivery order, with an ultimate completion date of September 11, 2025, represents a competitively awarded contract with no set-aside designation. The pharmaceutical product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate office and serves as...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,176.72 for Mounjaro 5 mg/0.5 ml pen (tirzepatide injection), a GLP-1 receptor agonist used for diabetes management. This firm fixed-price delivery order, awarded on August 11, 2025, with ultimate completion by August 12, 2025, was competitively awarded with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a $3,537.17 firm fixed price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Mounjaro (tirzepatide) 5 mg/0.5 mL pens in 0.5 mL unit doses. The contract, which is a non-set-aside competitive award with an ultimate completion date of July 25, 2025, will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,088.36 to AmerisourceBergen Drug Corp for the supply of Mounjaro (tirzepatide) 15 mg/0.5 mL pens on September 15, 2025. This firm fixed-price, non-set-aside delivery order, which is due for completion by September 16, 2025, represents a single transaction under AmerisourceBergen's larger pharmaceutical supply agreement with the federal government. The product will be delivered to AmerisourceBergen's corporate office...
- The Defense Logistics Agency awarded a $18,662.14 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Mounjaro (tirzepatide) 10 mg/0.5 mL pens on August 19, 2025, with completion required by August 20, 2025. This award was made without a set-aside designation through open competition. The order will be fulfilled from AmerisourceBergen's location in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. AmerisourceBergen Drug Corp is a major...
- The Defense Logistics Agency awarded a delivery order valued at $12,759.36 to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Mounjaro (tirzepatide) 7.5 mg/0.5 mL pen injectors. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and is scheduled for completion by July 28, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, where the company maintains its headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $11,125.48 to AmerisourceBergen Drug Corp for Mounjaro 5 mg/0.5 mL pens (tirzepatide injection), a diabetes medication, with completion targeted for September 15, 2025. This competitive, firm fixed-price delivery order represents a non-set-aside award to the pharmaceutical distributor's corporate office location in Conshohocken, Pennsylvania. The award falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- SPE2DB24D1201Indefinite Delivery Contract
- SPE2DB24D1201-SPE2DB25FJEFEDelivery Order
The Defense Logistics Agency awarded a $60,990.95 delivery order to AmerisourceBergen Drug Corp on September 16, 2025, for the supply of Mounjaro 10 mg/0.5 mL pens (tirzepatide), a diabetes treatment medication. This firm fixed-price delivery order, with an ultimate completion date of September 17, 2025, represents a non-competitive award under AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary distribution operations. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999.00 IDC with DLA Troop Support Medical (SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical procurement vendor, maintains an extensive portfolio of federal contracts supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support Defense Health Agency operations and other government healthcare systems worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $61.0k | 9/16/25 |